AlphaQuest LLC Boosts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

AlphaQuest LLC increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.0% in the 4th quarter, HoldingsChannel reports. The fund owned 12,780 shares of the specialty pharmaceutical company’s stock after buying an additional 374 shares during the quarter. AlphaQuest LLC’s holdings in Collegium Pharmaceutical were worth $366,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC boosted its position in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the period. Virtus Fund Advisers LLC bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at $72,000. KBC Group NV lifted its stake in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in Collegium Pharmaceutical by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after buying an additional 642 shares in the last quarter.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 26,067 shares of Collegium Pharmaceutical stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the completion of the sale, the executive vice president now directly owns 108,137 shares of the company’s stock, valued at $3,081,904.50. The trade was a 19.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now directly owns 165,246 shares in the company, valued at $4,959,032.46. The trade was a 5.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,961 shares of company stock worth $3,146,634. Insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $29.10 on Friday. The business’s 50 day moving average price is $30.85 and its 200-day moving average price is $33.05. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The company has a market cap of $916.24 million, a P/E ratio of 12.54 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.